This is a promotional email for UK Healthcare Professionals, sent on behalf of Takeda UK Ltd.
Prescribing Information and Adverse Event reporting can be found at the end of this email.
Problems viewing this email? View it in your browser

Adult ADHD medication: an assessment of efficacy and tolerability by Professor Cortese et al.

The meta-analysis by Professor Cortese et al. examined 133 clinical trials to assess the efficacy, tolerability and acceptability of ADHD (attention-deficit hyperactivity disorder) medications, with the findings providing a comprehensive evidence base to inform on the choice of ADHD medications.¹

Watch an animation of the Cortese et al. meta-analysis here

(Clicking this link/icon will take you through to an animation, initiated and developed by Takeda)

The adult meta-analysis included:

■

52 trials with a total of 8,131 patient participants.¹

■

A comparison of double-blind, randomised, controlled, clinical trials, to assess oral medications for ADHD which included methylphenidate^*, amphetamines and atomoxetine.¹

Primary focus on the comparative efficacy and tolerability.

Secondary focus on the patients’ quality of life.

^*Not all methylphenidate products are licensed for adult ADHD, individual product SPCs should be consulted before prescribing.

And concluded that amphetamines were the preferred first‑choice medication for the short‑term treatment of adults with ADHD.¹

Elvanse Adult is lisdexamfetamine dimesylate, a once-daily amphetamine used in the management of ADHD.²

How could Elvanse Adult help your patients better manage their adult ADHD symptoms?

■

Recommended by the National Institute for Health and Care Excellence (NICE) as a first line medication choice for adults with ADHD.³

■

Prodrug technology for consistent symptom control.^4-6

■

Taken once-daily for 14-hour core symptom control.^2,6

■

Significantly improved executive function* and quality of life vs. placebo at 10 weeks.^7,8

■

The most frequently reported adverse reactions (≥1/10) with Elvanse Adult are decreased appetite, dry mouth, headache and insomnia.²

*As measured by the validated, self-reported Brown Attention-Deficit Disorder Scale (BADDS)

Find out more about Elvanse Adult here

(Clicking this button will take you to a Takeda resource on BMJ.com for ADHD/Elvanse Adult.)

Elvanse Adult is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in adults.²

Elvanse Adult is not indicated in all adult patients and the decision to use the medicinal product must take into consideration the profile of the patient, including a thorough assessment of the severity and chronicity of the patient’s symptoms, the potential for abuse, misuse or diversion, and clinical response to any previous pharmacotherapies for the treatment of ADHD.²

Elvanse Adult treatment must be under the supervision of a specialist in behavioural disorders.²

References:

Cortese S et al. The Lancet Psychiatry 2018;5(9):727–38;

Elvanse Adult Summary of Product Characteristics. Available at www.medicines.org.uk (Accessed January 2023)

NICE guidelines NG87 (2018). Attention deficit hyperactivity disorder: diagnosis and management. Available at nice.org.uk/guidance/ng87 (accessed January 2023);

Ermer JC et al. Clin Drug Investig 2016;36(9):341–56;

Ermer JC et al. J Clin Pharmacol 2010;50(9):1001–10;

Wigal T et al. Behav Brain Funct 2010;6(9):34;

Adler LA et al. J Clin Psychiatry 2013;74(9):694–702;

Adler LA et al. BMC Psychiatry 2013;13(9):253;

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com

Click here for Prescribing Information

Job Code: C-APROM/GB/ELVA/0045
Date of Preparation: January 2023

©2023 Takeda UK Limited. All rights reserved. Takeda® and the Takeda Logo® are registered trademarks of Takeda. Pharmaceutical Company Limited. Takeda UK Limited, 1 Kingdom Street, London, W2 6BD, United Kingdom.

This email has been forwarded to you by Data4NHS, on behalf of Takeda UK Ltd.
Manage your Data4NHS profile by submitting your changes HERE.
View our privacy policy HERE.
UNSUBSCRIBE.